title: P300 changes in major depressive disorders with and without psychotic features.
abstract: BACKGROUND
  Although there are many P300 studies in depressive patients, only a few studies have focused on the effects of psychotic features in depression and of response to antidepressant treatment on P300. This study was designed to investigate possible differences in the P300 component of event-related potentials in depressed patients with and without psychotic features and if any, to see whether these changes altered with treatment of depression.
  
  
  METHODS
  Thirty-six patients with major depressive disorder diagnosed according to DSM-IV, and 20 healthy control subjects were involved in the study. Sixteen of the patients had psychotic features. Auditory P300 was recorded before treatment and after remission.
  
  
  RESULTS
  Pretreatment P300 latencies were significantly prolonged both in patients with and without psychotic features compared to controls. Pretreatment P300 amplitudes were significantly decreased only in the patients with psychotic features. After treatment of depression, delayed P300 latencies in both patient groups and decreased P300 amplitude in the patient group with psychotic features were normalized.
  
  
  CONCLUSIONS
  The medication status of the patient was heterogeneous.
  
  
  CONCLUSIONS
  Since the impairment seems to be improved by drug treatment, prolonged P300 latency might be a state marker for a major depressive episode, and decreased P300 amplitude which is correlated with paranoid ideation might be more associated with psychotic subtype.
authors.affiliation: Erciyes University School of Medicine Psychiatry Department, 38039, Kayseri, Turkey. alsaf@superonline.com
authors.forename: Fatih
authors.initials: F
authors.lastname: Karaaslan
authors.forename: Ali Saffet
authors.initials: AS
authors.lastname: Gonul
authors.forename: Aslan
authors.initials: A
authors.lastname: Oguz
authors.forename: Erdogan
authors.initials: E
authors.lastname: Erdinc
authors.forename: Ertugrul
authors.initials: E
authors.lastname: Esel
mesh_terms: D000328:Adult; D000341:Affective Disorders, Psychotic / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002540:Cerebral Cortex / Q000187:drug effects / Q000503:physiopathology; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects; D018913:Event-Related Potentials, P300 / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D010868:Pimozide / Q000627:therapeutic use; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D012016:Reference Values; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D007099:Imipramine; D010868:Pimozide; D017367:Selective Serotonin Reuptake Inhibitors